HHLA1

Across TCGA pan-cancer cohorts, HHLA1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HHLA1 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HHLA1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HHLA1 expression acts as an unfavorable survival marker.

LIHC and UCEC are the cancer types where HHLA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.020	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

HHLA1–LIHC (DFS)

Open the LIHC breakdown →